Prostate Cancer Update

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:
Treatment approach for AKT-mutated prostate cancer — Question from Neeraj Agarwal, MD, FASCO (0:00)
Case: A man in his late 60s with de novo metastatic hormone-sensitive prostate cancer with widespread skeletal metastases and PTEN loss on next-generation sequencing receives relugolix/darolutamide with chemotherapy and experiences PSA decline that plateaus at approximately 1 ng/mL — Rana R McKay, MD, FASCO (10:29)

CME information and select publications

Featuring perspectives from Dr Karim Fizazi, Dr Daniel George and Dr Elisabeth I Heath, moderated by Dr Heath, including the following topics:
Role of PTEN deficiency in tumorigenesis of prostate cancer and optimal approach to PTEN assessment — Question from Neeraj Agarwal, MD, FASCO (0:00)
Case: A man in his late 60s with a history of nonmetastatic hormone-sensitive prostate cancer (HSPC) that progressed to metastatic HSPC with PTEN loss by next-generation sequencing of primary archival tissue from 2017 receives abiraterone for 2 years — Rana R McKay, MD, FASCO (8:26)

CME information and select publications

Featuring perspectives from Dr Rahul Aggarwal, Dr Matthew D Galsky and Dr Tian Zhang, including the following topics:
Introduction: Welcome GU Oncology Fellows! (0:00)
Prostate Cancer — Dr Aggarwal (12:48)
Urothelial Bladder Cancer — Dr Galsky (45:01)
Renal Cell Carcinoma — Dr Zhang (1:10:52)

CME information and select publications

Featuring perspectives from Prof Yohann Loriot, including the following topics:
Case: A man in his early 80s with metastatic urothelial bladder cancer (mUBC) receives enfortumab vedotin (EV)/pembrolizumab but experiences immune-related adverse events requiring steroids and then develops neuropathy due to EV — Nazli Dizman, MD (0:00)
Case: A man in his early 70s with diabetes who received adjuvant nivolumab for FGFR3-mutant metastatic urothelial cancer receives first-line EV monotherapy and experiences hyperglycemia and cancer progression, then receives erdafitinib and experiences elevated phosphase, Grade 2 diarrhea and stomatitis and eventual disease progression — Jacqueline T Brown, MD (7:00)
Case: A man in his late 80s with mUBC receives first-line EV/pembrolizumab and develops pneumonitis — Fern Anari, MD (17:40)

CME information and select publications

Featuring perspectives from Prof Yohann Loriot, including the following topics:
Case: A man in his early 80s with Parkinson disease and a history of renal transplant presents with metastatic urothelial bladder cancer (UBC) and receives first-line enfortumab vedotin (EV) with a good response but develops neuropathy and skin toxicity — Jacqueline T Brown, MD (0:00)
Case: A man in his early 90s with excellent PS and locally advanced UBC receives EV and pembrolizumab as palliative treatment, develops neuropathy, discontinues the EV and continues pembrolizumab with no toxicity — Catherine Fahey, MD, PhD (12:01)
Case: A woman in her late 50s with metastatic UBC receives EV with pembrolizumab on a clinical trial and experiences a response but develops diarrhea and pruritus — Fern Anari, MD (21:43)

CME information and select publications